Diabetes, Vol 44, Issue 9 1059-1065, Copyright © 1995 by American Diabetes Association

ARTICLES

Acute hyperinsulinemia decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM

MH Cummings, GF Watts, AM Umpleby, TR Hennessy, JM Kelly, NC Jackson and PH Sonksen
Department of Medicine, St. Thomas' Hospital, United Medical and Dental School of Guys Hospital, London, U.K.

In a randomized crossover study, we measured the hepatic secretion rate of very-low-density lipoprotein (VLDL) apolipoprotein B-100 (apoB) in seven patients with well-controlled non-insulin-dependent diabetes mellitus (NIDDM) (HbA1 8.4 +/- 0.4% [mean +/- SE]) on two occasions: during a 13-h hyperinsulinemic (plasma insulin concentration 586 +/- 9.7 pmol/l) euglycemic (plasma glucose concentration 5.2 +/- 0.1 mmol/l) clamp; and during a 13-h saline (control) infusion. After 5 h of the hyperinsulinemic euglycemic clamp (or saline infusion) when a new steady state of apoB turnover was reached, [1-(13)C]leucine was administered by a primed (1 mg/kg), constant 8-h infusion (1 mg.kg-1. h-1). VLDL apoB isotopic enrichment was determined with gas chromatography-mass spectrometry, and a monoexponential model was used to calculate the fractional secretion rate of VLDL apoB. VLDL apoB secretion rate was significantly reduced during the hyperinsulinemic euglycemic clamp compared with the saline study (12.2 +/- 3.6 vs. 24.5 +/- 7.1 mg.kg-1.day-1, P = 0.001), but there was no change in the fractional catabolic rate of VLDL apoB. Concomitantly, plasma concentrations of nonesterified fatty acids (NEFAs), glycerol, and triglycerides (TGs) were significantly lower during the hyperinsulinemic euglycemic clamp compared with the saline study (NEFAs, P < 0.001; glycerol, P = 0.005; TGs P = 0.004). We conclude that acute hyperinsulinemia decreases the hepatic secretion rate of VLDL apoB in NIDDM, probably in part due to reduction in the delivery of NEFA and glycerol substrate to the liver.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				R. Ramakrishnan Studying apolipoprotein turnover with stable isotope tracers: correct analysis is by modeling enrichments J. Lipid Res., December 1, 2006; 47(12): 2738 - 2753. [Abstract] [Full Text] [PDF]

				G D Kolovou, K K Anagnostopoulou, and D V Cokkinos Pathophysiology of dyslipidaemia in the metabolic syndrome Postgrad. Med. J., June 1, 2005; 81(956): 358 - 366. [Abstract] [Full Text] [PDF]

				S. Alam, M. Stolinski, C. Pentecost, M. A. Boroujerdi, R. H. Jones, P. H. Sonksen, and A. M. Umpleby The Effect of a Six-Month Exercise Program on Very Low-Density Lipoprotein Apolipoprotein B Secretion in Type 2 Diabetes J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 688 - 694. [Abstract] [Full Text] [PDF]

				G. F. Watts, P. H. R. Barrett, J. Ji, A. P. Serone, D. C. Chan, K. D. Croft, F. Loehrer, and A. G. Johnson Differential Regulation of Lipoprotein Kinetics by Atorvastatin and Fenofibrate in Subjects With the Metabolic Syndrome Diabetes, March 1, 2003; 52(3): 803 - 811. [Abstract] [Full Text] [PDF]

				F. Pont, L. Duvillard, E. Florentin, P. Gambert, and B. Verges Early Kinetic Abnormalities of ApoB-Containing Lipoproteins in Insulin-Resistant Women With Abdominal Obesity Arterioscler. Thromb. Vasc. Biol., October 1, 2002; 22(10): 1726 - 1732. [Abstract] [Full Text] [PDF]

				D. C. Chan, G. F. Watts, P. H. R. Barrett, T. A. Mori, L. J. Beilin, and T. G. Redgrave Mechanism of Action of a 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor on Apolipoprotein B-100 Kinetics in Visceral Obesity J. Clin. Endocrinol. Metab., May 1, 2002; 87(5): 2283 - 2289. [Abstract] [Full Text] [PDF]

				A. Harbis, C. Defoort, H. Narbonne, C. Juhel, M. Senft, C. Latgé, B. Delenne, H. Portugal, C. Atlan-Gepner, B. Vialettes, et al. Acute Hyperinsulinism Modulates Plasma Apolipoprotein B-48 Triglyceride--Rich Lipoproteins in Healthy Subjects During the Postprandial Period Diabetes, February 1, 2001; 50(2): 462 - 469. [Abstract] [Full Text]

				D. B. Pawlak, J. M. Bryson, G. S. Denyer, and J. C. Brand-Miller High Glycemic Index Starch Promotes Hypersecretion of Insulin and Higher Body Fat in Rats without Affecting Insulin Sensitivity J. Nutr., January 1, 2001; 131(1): 99 - 104. [Abstract] [Full Text]

				D. V. Chirieac, L. R. Chirieac, J. P. Corsetti, J. Cianci, C. E. Sparks, and J. D. Sparks Glucose-stimulated insulin secretion suppresses hepatic triglyceride-rich lipoprotein and apoB production Am J Physiol Endocrinol Metab, November 1, 2000; 279(5): E1003 - E1011. [Abstract] [Full Text] [PDF]

				M. Axelsen, P. Lonnroth, R. A. Lenner, M.-R. Taskinen, and U. Smith Suppression of nocturnal fatty acid concentrations by bedtime carbohydrate supplement in type 2 diabetes: effects on insulin sensitivity, lipids, and glycemic control Am. J. Clinical Nutrition, May 1, 2000; 71(5): 1108 - 1114. [Abstract] [Full Text] [PDF]

				S. Bioletto, A. Golay, R. Munger, B. Kalix, and R. W James Acute hyperinsulinemia and very-low-density and low-density lipoprotein subfractions in obese subjects1 Am. J. Clinical Nutrition, February 1, 2000; 71(2): 443 - 449. [Abstract] [Full Text] [PDF]

				A. Suga, T. Hirano, S. Inoue, M. Tsuji, T. Osaka, Y. Namba, M. Miura, and M. Adachi Plasma leptin levels and triglyceride secretion rates in VMH-lesioned obese rats: a role of adiposity Am J Physiol Endocrinol Metab, April 1, 1999; 276(4): E650 - E657. [Abstract] [Full Text] [PDF]

				L. Mantha and Y. Deshaies beta -Adrenergic modulation of triglyceridemia under increased energy expenditure Am J Physiol Regulatory Integrative Comp Physiol, June 1, 1998; 274(6): R1769 - R1776. [Abstract] [Full Text] [PDF]

				R. Malmstrom, C. J. Packard, T. D. G. Watson, S. Rannikko, M. Caslake, D. Bedford, P. Stewart, H. Yki-Jarvinen, J. Shepherd, and M.-R. Taskinen Metabolic Basis of Hypotriglyceridemic Effects of Insulin in Normal Men Arterioscler. Thromb. Vasc. Biol., July 1, 1997; 17(7): 1454 - 1464. [Abstract] [Full Text]